Tags : Three

Sangamo Signs a Worldwide License Agreement with Novartis to Develop

Shots: Sangamo to receive $75M upfront within 30 days, $720M milestone payments including up to $420M in development milestones and up to $300M in commercial milestones plus royalties on sales of the product. Additionally, Sangamo to take care of certain research and manufacturing activities funded by Novartis Novartis to get exclusive license rights of ZFP-TFs […]Read More

Three Pharma Companies Launch Favipiravir to Treat COVID-19 in India

Shots: Jenburkt became the second company to launch Favivent (favipiravir) to treat mild to moderate COVID-19 symptoms at a price of ​Rs. 39/tablet Cipla receives the DCGI approval for Ciplenza (favipiravir, 200mg) targeting the unmet medical needs for COVID-19 treatment options in the country through restricted emergency use. The company will launch Ciplenza in the […]Read More

Merck Reports Three Major Initiatives Focusing on Developing Vaccine Against

Shots: Merck will acquire all outstanding shares of Themis in exchange for an undisclosed cash payment. The acquisition follows the ongoing collaboration between the two companies to develop vaccine candidates utilizing the measles virus vector platform and is expected to accelerate the development of Themis’ COVID-19 vaccine candidate with the anticipated initiation of clinical study […]Read More

Bayer Signs a Three Year Multi Target AI-based Agreement with

Shots: Exscientia to get up to $266.2M including upfront, research payments and clinical milestones plus royalties on sales. Bayer to get rights for the developed therapies under collaboration   The partners will focus on early research projects combining Exscientia’s AI drug discovery platform and drug design know-how with Bayer’s data and drug discovery capabilities for […]Read More

Yas Holding to Acquire Stake in Alvotech and Signs an

Shots: Alvotech to receive ~$45M as up front, equity investment, milestone while Yas Holding has acquired a 2.5% stake in Alvotech business and get rights to commercialize Alvotech’s three biosimilar candidates in MENA region The investment will complement Yas holding an existing portfolio and expands its footprints in health & pharmaceutical sector both in the […]Read More

Alvogen Signs an Exclusive Commercialization Agreement with Three Pharma Companies

Shots: Alvogen collaborates with PharmBio, Kamada and Jamp to commercialize PF708 for the treatment of osteoporosis in South Korea, Israel and Canada respectively The focus of the collaboration is to build strong commercial networks in South Korea, Israel and Canada and to gain commercial expertise within the territories PF708 is a biosimilar referencing Eli Lilly’s […]Read More

Allergan to Launch Three REFRESH RELIEVA Lubricant Eye Drops Expanding

Shots: Allergan launches three new OTC REFRESH RELIEVA products: REFRESH RELIEVA, REFRESH RELIEVA PF multidose and REFRESH RELIEVA for contacts to relieve discomfort due to eye dryness and to prevent irritation The launch of three unique options to treat patients with dry, irritated eyes and contact lens dryness expands Allergan’s artificial tear, REFRESH portfolio. REFRESH […]Read More